Home › Migraine › Tennessee
Migraine clinical trials in Tennessee
7 studies for Migraine are looking for participants at sites in Tennessee.
Cities in Tennessee
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Vanderbilt Medical Center, Nashville
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Nov 13, 2026 · NCT06972056Study of EVO756 in Adults With Migraine
- Campbell Clinical Research, Franklin
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Nov 13, 2026 · NCT07616128A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- WR-ClinSearch, LLC, Chattanooga
- Access Clinical Trials, Inc, Nashville
- Clinical Research Associates, Inc., Nashville
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 2, 2026 · NCT07645924A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Access Clinical Trials Inc /ID# 270280, Nashville
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Oct 9, 2026 · NCT06810505Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
- CNS Healthcare, Memphis
- Clinical Research Associates, Inc., Nashville
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Oct 9, 2026 · NCT07646613Responding With Evidence and Access for Childhood Headaches
- University of Tennessee Health Science Center/ LeBonheur Children's Hospital, Memphis
Recruiting
Ages 10 to 17 · All sexes · Updated Sep 21, 2026 · NCT05889624Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Access Clinical Trials, Inc. /ID# 228002, Nashville
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Sep 14, 2026 · NCT05125302From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.